Drugs / ALN-TTRSC04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05661916 | Jan 2023 → Sep 2025 | — | Alnylam Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-17 | Alnylam Pharmaceuticals | Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-TTRSC04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05661916 ↗ |
| Route | Subcutaneous | “ALN-TTRSC04 will be administered by subcutaneous (SC) injection.” NCT05661916 ↗ |